ANG Lifesciences India Ltd

ANG Lifesciences India Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹33.00 crores, reported a quarterly net loss of ₹4.75 crores for Q3 FY26 ended December 2025, marking a 61.02% sequential deterioration from the previous quarter's loss of ₹2.95 crores. On a year-on-year basis, losses expanded 8.48% from ₹5.19 crores in Q3 FY25, as the company grapples with a sustained revenue contraction and negative operating margins.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2023. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook.

ANG Lifesciences has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. The pharmaceutical and biotechnology company’s recent assessment highlights concerns across multiple parameters, signalling a cautious outlook for investors amid persistent underperformance and financial strain.

ANG Lifesciences India has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, reflecting a rare scenario of sustained demand and no selling pressure, potentially signalling a multi-day circuit phenomenon.

ANG Lifesciences India has witnessed extraordinary buying momentum, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals intense demand and the possibility of a multi-day circuit scenario, drawing significant attention from investors and market watchers alike.

ANG Lifesciences India has witnessed extraordinary buying momentum today, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon highlights intense demand and the possibility of a sustained multi-day circuit scenario, setting the stage for close investor attention in the Pharmaceuticals & Biotechnology sector.

ANG Lifesciences India has witnessed a remarkable surge in buying activity, with the stock hitting the upper circuit and registering only buy orders in the queue. This unusual market behaviour signals intense demand and the possibility of a multi-day circuit scenario, drawing significant attention from investors and market watchers alike.

ANG Lifesciences India is experiencing severe selling pressure, with the stock registering a sharp decline of 4.99% today and no buyers visible in the order book. This marks the seventh consecutive day of losses, reflecting a sustained period of distress selling that has significantly impacted the stock’s performance across multiple time frames.

ANG Lifesciences India is currently experiencing severe selling pressure, with the stock registering a lower circuit and an absence of buyers on the order book. The pharmaceutical and biotechnology company has seen a continuous decline over the past week, signalling distress selling and heightened market caution.

ANG Lifesciences India is currently experiencing severe selling pressure, with the stock registering a fifth consecutive day of losses and no buyers visible in the order book. The pharmaceutical and biotechnology company’s shares have underperformed the broader market significantly, signalling distress selling and a challenging outlook for investors.